ERADICATE, NCT04484818: Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The Study |
|
|
| Active, not recruiting | 3 | 27 | US | Darolutamide, Antiandrogen ODM-201, BAY 1841788, BAY-1841788, BAY1841788, ODM 201, ODM-201, Goserelin Acetate, ZDX, Zoladex, Leuprolide Acetate, A-43818, Abbott 43818, Abbott-43818, Carcinil, Depo-Eligard, Eligard, Enanton, Enantone, Enantone-Gyn, Ginecrin, LEUP, Leuplin, Leuprorelin Acetate, Lucrin, Lucrin Depot, Lupron, Lupron Depot, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron Depot-Ped, Lutrate, Procren, Procrin, Prostap, TAP-144, Trenantone, Uno-Enantone, Viadur, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment, Triptorelin, 6-D-Tryptophan-LH-RH, 6-D-Tryptophanluteinizing Hormone-releasing Factor, AY-25650, CL-118,532, Detryptoreline | ECOG-ACRIN Cancer Research Group, National Cancer Institute (NCI) | Prostate Carcinoma | 12/25 | 05/28 | | |
NCT04126070: Nivolumab + Docetaxel + ADT in MHSPC Patients with DDRD or Inflamed Tumors |
|
|
| Active, not recruiting | 2 | 60 | US | Androgen Deprivation Therapy, Leuprolide, Lupron Depot, Goserelin acetate, Zoladex, Degarelix, Firmagon, Nivolumab, Docetaxel, Taxotere | Xiao X. Wei, MD, Bristol-Myers Squibb | Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma, Metastasis Prostate Adenocarcinoma | 10/24 | 06/25 | | |
